Loading stock data…
$22.43-0.68 (-2.94%)
uniQure N.V.
uniQure N.V. in the Healthcare sector is trading at $22.43 with a market capitalization of $3.4B. Wall Street consensus targets $60.37 (11 analysts), implying a +169.2% move over the next 12 months. The stock is currently 69% below its 52-week high of $71.50, remaining 24.3% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $5.84M↑ | $3.56M↓ | $5.57M↑ | $3.70M↓ | $5.26M |
| Gross Profit | $5.49M↑ | $3.34M↓ | $5.13M↑ | $3.30M↓ | $4.61M |
| Operating Income | -$44.68M↓ | -$44.27M↑ | -$51.49M↓ | -$49.49M↓ | -$42.88M |
| Net Income | -$81.06M↓ | -$53.53M↓ | -$37.09M↑ | -$80.53M↓ | -$37.72M |
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding....